Puma Biotechnology (PBYI) Free Cash Flow (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Free Cash Flow data on file, last reported at $15.4 million in Q1 2026.

• Quarterly Free Cash Flow rose 334.13% year-over-year to $15.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (up 71.96% YoY) and the FY2025 annual result came in at $41.7 million, up 7.38% from the prior year.
• Free Cash Flow grew to $15.4 million in Q1 2026, from $14.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $17.3 million in Q3 2022 to a low of -$26.9 million in Q1 2022.
• A 5-year average of $6.3 million and a median of $10.4 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 18648.65% — and 2025, when it soared 1289.68%.
• Tracing PBYI's Free Cash Flow over 5 years: stood at $7.7 million in 2022, then surged by 35.74% to $10.4 million in 2023, then soared by 49.3% to $15.6 million in 2024, then decreased by 7.17% to $14.5 million in 2025, then rose by 6.65% to $15.4 million in 2026.
• The last three Free Cash Flow figures came in at $15.4 million (Q1 2026), $14.5 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.